Methionine Synthase Reductase A66G Polymorphism is not Associated with Breast Cancer Susceptibility - a Meta-analysis

Background: Several studies have investigated the association between methionine synthase reductase(MTRR) A66G polymorphism and breast cancer risk, but controversial results were yielded. Therefore, weperformed a meta-analysis to provide a more robust estimate of the effect of this polymorphism on susceptibilityto breast cancer. Materials and
Methods:Case-control studies investigating the relationship between MTRRA66G polymorphism and breast cancer risk were included by searching PubMed, EMBASE, China NationalKnowledge Infrastructure and Wanfang Database. Either fixed-effects or random-effects models were appliedto calculate odds ratios(ORs) and 95% confidence intervals (CIs) by RevMan5.2 software.
Results: A total of9 studies bearing 7,097 cases and 7,710 controls were included in the meta-analysis. The results were that thecombined ORs and 95%CIs of MTRR 66AG, GG, (AG+GG) genotypes were 0.98(0.91-1.05), 1.06(0.97-1.16)and 1.02(0.94-1.10), respectively with p=0.52, 0.19 and 0.65. We also performed subgroup analysis by specificethnicity. The results of the combined analysis of MTRR 66AG, GG, (AG+GG) genotypes and breast cancer inAsian descent were Z=0.50, 0.53 and 0.21, with p all>0.05; for breast cancer in Caucasian descent, the results wereZ=1.14, 1.65 and 0.43, with p all>0.05.
Conclusions: Our findings suggested that MTRR A66G polymorphismwas not associated with breast cancer susceptibility.